USANA Health Sciences Inc. $(USNA)$ announced its financial results for the fiscal second quarter ending June 28, 2025. The company reported consolidated net sales of $236 million, marking an 11% increase compared to $213 million in the same quarter of the previous year. Net earnings for the quarter were $9.7 million, a decrease from $10.4 million year-over-year. The diluted earnings per share $(EPS)$ was $0.52, slightly down from $0.54 in the second quarter of 2024. However, the adjusted diluted EPS rose significantly to $0.74 from $0.54. Adjusted EBITDA also saw an increase, reaching $30 million compared to $27 million in the previous year. The company reiterated its fiscal year 2025 outlook, projecting consolidated net sales between $920 million and $1.0 billion. Net earnings are expected to range from $29 million to $41 million, with diluted EPS anticipated to be between $1.50 and $2.20. Adjusted diluted EPS is forecasted to be between $2.35 and $3.00, and adjusted EBITDA is expected to range from $107 million to $123 million. Operationally, USANA highlighted the repayment of a $23 million credit facility used in the Hiya transaction, leaving the company debt-free. Additionally, USANA repurchased 528,000 shares for $15 million during the quarter, with approximately $34 million remaining under the current share repurchase authorization. The company also reported having $151 million in cash and cash equivalents at the end of the quarter.